Business
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO. “Having just presented the data from our PK and PD studies in two encore presentations at the Global Food Allergy Prevention Summit earlier this month, we are thrilled to be given the opportunity to continue to share both presentations at the upcoming Aspen Allergy Conference,” said Daniel Barber, Chief Executive Officer of Aquestive. “Anaphylm continues to be a primary focus of our development program as it has the potential to provide a highly differentiated product to patients. Anaphylm is the first oral film candidate in development for the emergency treatment of severe allergic reactions, including anaphylaxis.” Poster Title: Pharmacokinetics and Pharmacodynamics of Epinephrine Sublingual Film Versus Intra-Muscular EpinephrinePresentation Time: Monday, July 31, 5:00 – 7:00 PM MDTLead Author: David Golden, M.D., Medstar Franklin Square Hospital Poster Title: Impact of Food Exposure on the Pharmacokinetics of Epinephrine Sublingual FilmPresentation Time: Monday, July 31, 5:00 – 7:00 PM MDT Lead Author: John Oppenheimer, M.D., UMDNJ Rutgers University School of Medicine About AnaphylaxisAnaphylaxis is a serious systemic hypersensitivity reaction with that is rapid in onset and potentially fatal. As many as 49 million people in the United States are at chronic risk for anaphylaxis. Lifetime prevalence in the US is at least 5%, or more than 16 million people. Direct costs of anaphylaxis have been estimated at $1.2 billion per year, with direct expenditures of $294 million for epinephrine, and indirect costs of $609 million. The frequency of hospital admissions for anaphylaxis has increased 500–700% in the last 10–15 years. Of patients who previously experienced anaphylaxis, 52% had never received an epinephrine auto-injector prescription, and 60% did not have an auto-injector...